732 related articles for article (PubMed ID: 30097887)
21. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.
Carmeli Y; Armstrong J; Laud PJ; Newell P; Stone G; Wardman A; Gasink LB
Lancet Infect Dis; 2016 Jun; 16(6):661-673. PubMed ID: 27107460
[TBL] [Abstract][Full Text] [Related]
22. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
Sharma R; Park TE; Moy S
Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862
[TBL] [Abstract][Full Text] [Related]
23. The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against β-lactamase-producing Enterobacteriaceae studied in an in vitro model of infection.
MacGowan A; Tomaselli S; Noel A; Bowker K
J Antimicrob Chemother; 2017 Mar; 72(3):762-769. PubMed ID: 28039276
[TBL] [Abstract][Full Text] [Related]
24. Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection.
Berkhout J; Melchers MJ; van Mil AC; Seyedmousavi S; Lagarde CM; Schuck VJ; Nichols WW; Mouton JW
Antimicrob Agents Chemother; 2016 Jan; 60(1):368-75. PubMed ID: 26525790
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam.
Singh R; Kim A; Tanudra MA; Harris JJ; McLaughlin RE; Patey S; O'Donnell JP; Bradford PA; Eakin AE
J Antimicrob Chemother; 2015 Sep; 70(9):2618-26. PubMed ID: 26024868
[TBL] [Abstract][Full Text] [Related]
26. Monte Carlo Simulation Methodologies for β-Lactam/β-Lactamase Inhibitor Combinations: Effect on Probability of Target Attainment Assessments.
Kidd JM; Stein GE; Nicolau DP; Kuti JL
J Clin Pharmacol; 2020 Feb; 60(2):172-180. PubMed ID: 31423601
[TBL] [Abstract][Full Text] [Related]
27.
Kazmierczak KM; Bradford PA; Stone GG; de Jonge BLM; Sahm DF
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249690
[No Abstract] [Full Text] [Related]
28. A mathematical model-based analysis of the time-kill kinetics of ceftazidime/avibactam against Pseudomonas aeruginosa.
Sy SKB; Zhuang L; Xia H; Beaudoin ME; Schuck VJ; Nichols WW; Derendorf H
J Antimicrob Chemother; 2018 May; 73(5):1295-1304. PubMed ID: 29415212
[TBL] [Abstract][Full Text] [Related]
29. A model-based analysis of pharmacokinetic-pharmacodynamic (PK/PD) indices of avibactam against Pseudomonas aeruginosa.
Sy SKB; Zhuang L; Xia H; Schuck VJ; Nichols WW; Derendorf H
Clin Microbiol Infect; 2019 Jul; 25(7):904.e9-904.e16. PubMed ID: 30394361
[TBL] [Abstract][Full Text] [Related]
30.
Stone GG; Bradford PA; Tawadrous M; Taylor D; Cadatal MJ; Chen Z; Chow JW
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32071051
[TBL] [Abstract][Full Text] [Related]
31. Ceftazidime/avibactam versus standard-of-care agents against carbapenem-resistant Enterobacteriaceae harbouring blaKPC in a one-compartment pharmacokinetic/pharmacodynamic model.
Barber KE; Pogue JM; Warnock HD; Bonomo RA; Kaye KS
J Antimicrob Chemother; 2018 Sep; 73(9):2405-2410. PubMed ID: 29939267
[TBL] [Abstract][Full Text] [Related]
32. Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections.
Shirley M
Drugs; 2018 Apr; 78(6):675-692. PubMed ID: 29671219
[TBL] [Abstract][Full Text] [Related]
33. Ceftazidime-Avibactam Activity against Aerobic Gram Negative Organisms Isolated from Intra-Abdominal Infections in United States Hospitals, 2012-2014.
Sader HS; Castanheira M; Flamm RK; Huband MD; Jones RN
Surg Infect (Larchmt); 2016 Aug; 17(4):473-8. PubMed ID: 27104633
[TBL] [Abstract][Full Text] [Related]
34. Ceftazidime-avibactam (CTZ-AVI) as a treatment for hospitalized adult patients with complicated intra-abdominal infections.
Gardiner BJ; Golan Y
Expert Rev Anti Infect Ther; 2016; 14(5):451-63. PubMed ID: 27042762
[TBL] [Abstract][Full Text] [Related]
35. Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections.
Falcone M; Paterson D
J Antimicrob Chemother; 2016 Oct; 71(10):2713-22. PubMed ID: 27432599
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological aspects and spectrum of action of ceftazidime-avibactam: a systematic review.
Tuon FF; Rocha JL; Formigoni-Pinto MR
Infection; 2018 Apr; 46(2):165-181. PubMed ID: 29110143
[TBL] [Abstract][Full Text] [Related]
37. Ceftazidime-avibactam for the treatment of complicated intra-abdominal infections.
Buckman SA; Krekel T; Muller AE; Mazuski JE
Expert Opin Pharmacother; 2016 Dec; 17(17):2341-2349. PubMed ID: 27758148
[TBL] [Abstract][Full Text] [Related]
38. Ceftazidime/avibactam: a novel cephalosporin/nonbeta-lactam beta-lactamase inhibitor for the treatment of complicated urinary tract infections and complicated intra-abdominal infections.
Hidalgo JA; Vinluan CM; Antony N
Drug Des Devel Ther; 2016; 10():2379-86. PubMed ID: 27528799
[TBL] [Abstract][Full Text] [Related]
39. A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia.
Qin X; Tran BG; Kim MJ; Wang L; Nguyen DA; Chen Q; Song J; Laud PJ; Stone GG; Chow JW
Int J Antimicrob Agents; 2017 May; 49(5):579-588. PubMed ID: 28363526
[TBL] [Abstract][Full Text] [Related]
40. Safety and Efficacy of Ceftazidime-Avibactam Plus Metronidazole in the Treatment of Children ≥3 Months to <18 Years With Complicated Intra-Abdominal Infection: Results From a Phase 2, Randomized, Controlled Trial.
Bradley JS; Broadhurst H; Cheng K; Mendez M; Newell P; Prchlik M; Stone GG; Talley AK; Tawadrous M; Wajsbrot D; Yates K; Zuzova A; Gardner A
Pediatr Infect Dis J; 2019 Aug; 38(8):816-824. PubMed ID: 31306396
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
